Fate Therapeutics, Inc.

NasdaqGM:FATE 주식 리포트

시가총액: US$280.9m

Fate Therapeutics 경영진

경영진 기준 점검 2/4

Fate Therapeutics CEO는 Bob Valamehr, Jan2025 에 임명되었습니다 의 임기는 1.42 년입니다. 총 연간 보상은 $2.25M, 26.7% 급여 및 73.3% 보너스(회사 주식 및 옵션 포함)로 구성됩니다. 는 $276.67K 가치에 해당하는 회사 주식의 0.098% 직접 소유합니다. 경영진과 이사회의 평균 재임 기간은 1.4 년과 6.9 년입니다.

핵심 정보

Bob Valamehr

최고경영자

US$2.2m

총 보수

CEO 급여 비율26.68%
CEO 재임 기간1.4yrs
CEO 지분 보유율0.1%
경영진 평균 재임 기간1.4yrs
이사회 평균 재임 기간6.9yrs

최근 경영진 업데이트

Recent updates

Seeking Alpha • Jun 24

Fate Therapeutics: FT819 Progress Keeps My Bull Case Alive

Summary Fate Therapeutics is a bet on their off-the-shelf cell therapies, which are now mostly centered on FT819 for lupus nephritis. I believe FT819 has made good progress since the last time I covered the stock. They’ve reported broader autoimmune data and are now planning RECLAIM-LN. Unfortunately, I think their recent removal from the Russell 3000 index could be a near-term headwind for the stock price itself. However, I don’t think this index removal will have a major impact on their underlying R&D progress with FT819. On balance, I still believe FATE offers good upside potential at these levels despite its inherent risks tied to RECLAIM-LN’s clinical data in the long run. Read the full article on Seeking Alpha
분석 기사 • Nov 25

Here's Why We're A Bit Worried About Fate Therapeutics' (NASDAQ:FATE) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, although...
분석 기사 • Aug 08

Here's Why We're Watching Fate Therapeutics' (NASDAQ:FATE) Cash Burn Situation

NasdaqGM:FATE 1 Year Share Price vs Fair Value Explore Fate Therapeutics's Fair Values from the Community and select...
분석 기사 • Apr 22

We're Keeping An Eye On Fate Therapeutics' (NASDAQ:FATE) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Feb 05

Fate Therapeutics Has Promising Off-The-Shelf Cell Therapies While Looking Cheap

Summary Fate Therapeutics uses iPSC and gene editing to offer scalable off-the-shelf therapies that could help oncology and immunology patients. Their pipeline has 3 interesting Phase 1 candidates for SLE, Solid Tumors, and B-cell lymphoma. But in my view, FT819 shows the most promising, as they recently achieved remission for one SLE patient. Valuation-wise, I think FATE’s low P/B relative to peers shows it is cheap, even though that’s partially due to its early-stage pipeline. The main risk I see with FATE is its inherently speculative R&D progress, but also its cash burn, which could become an issue by 2027. Other than that, I rate FATE a “Buy”. Read the full article on Seeking Alpha
분석 기사 • Jan 06

We're Keeping An Eye On Fate Therapeutics' (NASDAQ:FATE) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Nov 20

Fate Therapeutics: FT819 Finding Bodes Well For Future Of SLE Treatment Options

Summary Fate Therapeutics, Inc. reported positive phase 1 data for FT819 in treating moderate-to-severe Systemic Lupus Erythematosus, showing remission in one patient with fludarabine-free conditioning. A second study arm will test FT819 as an add-on to maintenance therapy without conditioning chemotherapy targeting SLE patients. Data from the first three patients will be presented at the American Society of Hematology Annual Meeting, being held between December 7th through 10th of 2024. FT522 is also being explored in phase 1 trials for the treatment of patients with relapsed/refractory B-cell lymphoma and B-cell mediated autoimmune disorders. Read the full article on Seeking Alpha
분석 기사 • Aug 21

Industry Analysts Just Made An Incredible Upgrade To Their Fate Therapeutics, Inc. (NASDAQ:FATE) Revenue Forecasts

Fate Therapeutics, Inc. ( NASDAQ:FATE ) shareholders will have a reason to smile today, with the analysts making...
분석 기사 • Aug 11

Is Fate Therapeutics (NASDAQ:FATE) In A Good Position To Invest In Growth?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Apr 29

Fate Therapeutics: Looking For A Potential Turnaround In 2024

Summary Fate Therapeutics has faced setbacks, including the termination of a partnership with Janssen Pharmaceuticals, but upcoming clinical milestones could reset the bull thesis. The company's iPSCs technology creates renewable off-the-shelf cell therapies for hematological malignancies and solid tumors. Fate Therapeutics has a healthy cash position and is expected to report positive data from clinical trials, potentially leading to exponential growth and significant market share. Read the full article on Seeking Alpha
분석 기사 • Apr 23

Fate Therapeutics, Inc.'s (NASDAQ:FATE) 28% Dip In Price Shows Sentiment Is Matching Revenues

Fate Therapeutics, Inc. ( NASDAQ:FATE ) shares have retraced a considerable 28% in the last month, reversing a fair...
분석 기사 • Feb 16

Fate Therapeutics, Inc. (NASDAQ:FATE) Held Back By Insufficient Growth Even After Shares Climb 57%

Despite an already strong run, Fate Therapeutics, Inc. ( NASDAQ:FATE ) shares have been powering on, with a gain of 57...
Seeking Alpha • Jan 26

Fate Therapeutics Update: A Rally Based On Little Increases Near-Term Risks

Summary Fate Therapeutics is a cell therapy-focused biotech that is overvalued and should be sold due to the risk of value erosion in 2024. The company's most advanced pipeline projects are FT576 and FT819, but no updates have been provided since the last article. The transition of their HER2-targeted CAR T-cell product, FT825, into phase 1 study is a significant development, but early data is needed to determine its potential. Read the full article on Seeking Alpha
분석 기사 • Dec 19

Fate Therapeutics, Inc.'s (NASDAQ:FATE) Shares Bounce 30% But Its Business Still Trails The Industry

The Fate Therapeutics, Inc. ( NASDAQ:FATE ) share price has done very well over the last month, posting an excellent...
분석 기사 • Sep 08

Is Fate Therapeutics (NASDAQ:FATE) In A Good Position To Deliver On Growth Plans?

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
분석 기사 • Jun 07

Benign Growth For Fate Therapeutics, Inc. (NASDAQ:FATE) Underpins Its Share Price

With a price-to-sales (or "P/S") ratio of 4x Fate Therapeutics, Inc. ( NASDAQ:FATE ) may be sending very bullish...
분석 기사 • May 08

Industry Analysts Just Upgraded Their Fate Therapeutics, Inc. (NASDAQ:FATE) Revenue Forecasts By 41%

Shareholders in Fate Therapeutics, Inc. ( NASDAQ:FATE ) may be thrilled to learn that the analysts have just delivered...
분석 기사 • Apr 17

Is Fate Therapeutics (NASDAQ:FATE) In A Good Position To Invest In Growth?

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
분석 기사 • Jan 10

We Think Fate Therapeutics (NASDAQ:FATE) Needs To Drive Business Growth Carefully

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

CEO 보수 분석

Bob Valamehr의 보수는 Fate Therapeutics의 수익에 비해 어떻게 변했나요?
날짜총 보수급여회사 수익
Mar 31 2026n/an/a

-US$130m

Dec 31 2025US$2mUS$600k

-US$136m

Sep 30 2025n/an/a

-US$156m

Jun 30 2025n/an/a

-US$172m

Mar 31 2025n/an/a

-US$176m

Dec 31 2024US$4mUS$525k

-US$186m

Sep 30 2024n/an/a

-US$178m

Jun 30 2024n/an/a

-US$176m

Mar 31 2024n/an/a

-US$190m

Dec 31 2023US$3mUS$500k

-US$161m

Sep 30 2023n/an/a

-US$173m

Jun 30 2023n/an/a

-US$212m

Mar 31 2023n/an/a

-US$235m

Dec 31 2022US$3mUS$455k

-US$282m

Sep 30 2022n/an/a

-US$294m

Jun 30 2022n/an/a

-US$254m

Mar 31 2022n/an/a

-US$233m

Dec 31 2021US$6mUS$430k

-US$212m

Sep 30 2021n/an/a

-US$197m

Jun 30 2021n/an/a

-US$212m

Mar 31 2021n/an/a

-US$185m

Dec 31 2020US$2mUS$390k

-US$173m

Sep 30 2020n/an/a

-US$149m

Jun 30 2020n/an/a

-US$117m

Mar 31 2020n/an/a

-US$112m

Dec 31 2019US$3mUS$375k

-US$98m

보상 대 시장: Bob의 총 보수(USD2.25M)는 US 시장에서 비슷한 규모 기업의 평균(USD1.63M)보다 높습니다.

보상과 수익: Bob의 보상은 지난 1년 동안 회사 실적과 일치했습니다.

CEO

Bob Valamehr (49 yo)

1.4yrs
재임 기간
US$2,248,568
보수

Dr. Bahram Valamehr, also known as Bob, Ph D, M.B.A., is President and CEO of Fate Therapeutics, Inc. since January 01, 2025 and serves as its Director since January 2025 and was its President of Research...

리더십 팀

이름직위재임 기간보수지분
Bahram Valamehr
President1.4yrsUS$2.25m0.098%
$ 276.7k
Kamal Adawi
CFO & Treasurerless than a yearUS$1.11m0%
$ 0
Cindy Tahl
Chief Legal & Compliance Officer and Corporate Secretary10.7yrsUS$1.11m0.54%
$ 1.5m
Jessica Francis
Senior Vice President of Human Resources & Operations1.4yrs데이터 없음데이터 없음
Martin Hosking
Head of Researchless than a year데이터 없음데이터 없음
Tunde Babalola
Senior Vice President of Technical Operations & Quality1.4yrs데이터 없음데이터 없음
Ryan Douglas
Senior Director of Investor Relations & Business Developmentless than a year데이터 없음데이터 없음
Andrew Henry
Senior Vice President of Clinical Operations2.4yrs데이터 없음데이터 없음
Yu Cai
Head of Intellectual Property & Assistant General Counsel1.4yrs데이터 없음데이터 없음
Kate Duvall
Corporate Controller1.2yrs데이터 없음데이터 없음
1.4yrs
평균 재임 기간
51yo
평균 나이

경험이 풍부한 관리: FATE의 경영진은 경험이 부족한 것으로 간주됩니다(평균 재임 1.4 년) — 신규 팀일 수 있습니다.

이사회 구성원

이름직위재임 기간보수지분
Bahram Valamehr
President1.4yrsUS$2.25m0.098%
$ 276.7k
William Rastetter
Independent Chairman14.6yrsUS$142.98k0.55%
$ 1.5m
Robert Epstein
Independent Director12.3yrsUS$123.71k0.031%
$ 87.6k
Michael Lee
Independent Director7.9yrsUS$104.09k0.0097%
$ 27.3k
Laura Hamill
Independent Directorno data데이터 없음데이터 없음
Matthew Abernethy
Independent Director1.1yrsUS$151.61k0%
$ 0
Karin Jooss
Independent Director7.3yrsUS$118.96k0.0084%
$ 23.7k
Shefali Agarwal
Independent Director6.9yrsUS$115.09k0.0090%
$ 25.3k
Yuan Xu
Independent Director4.8yrsUS$111.52k0.0074%
$ 20.9k
6.9yrs
평균 재임 기간
58yo
평균 나이

경험이 풍부한 이사회: FATE의 이사회는 경험이 있음으로 간주됩니다(평균 재임 6.9 년).

기업 분석 및 재무 데이터 상태

데이터최종 업데이트 (UTC 시간)
기업 분석2026/06/30 12:57
종가2026/06/29 00:00
수익2026/03/31
연간 수익2025/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지데이터기간미국 소스 예시 *
기업 재무제표10년
  • 손익계산서
  • 현금흐름표
  • 대차대조표
분석가 컨센서스 추정치+3년
  • 재무 예측
  • 분석가 목표주가
시장 가격30년
  • 주가
  • 배당, 분할 및 기타 조치
지분 구조10년
  • 주요 주주
  • 내부자 거래
경영진10년
  • 리더십 팀
  • 이사회
주요 개발10년
  • 회사 공시

* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Fate Therapeutics, Inc.는 25명의 분석가가 다루고 있습니다. 이 중 12명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가기관
Jack AllenBaird
Tazeen AhmadBofA Global Research
Amanda MurphyBTIG